NZ602108A - Solid forms comprising a cyclopropyl amide derivative - Google Patents

Solid forms comprising a cyclopropyl amide derivative

Info

Publication number
NZ602108A
NZ602108A NZ602108A NZ60210811A NZ602108A NZ 602108 A NZ602108 A NZ 602108A NZ 602108 A NZ602108 A NZ 602108A NZ 60210811 A NZ60210811 A NZ 60210811A NZ 602108 A NZ602108 A NZ 602108A
Authority
NZ
New Zealand
Prior art keywords
solid forms
amide derivative
cyclopropyl amide
schizophrenia
compound
Prior art date
Application number
NZ602108A
Other languages
English (en)
Inventor
Craig D Collins
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NZ602108A publication Critical patent/NZ602108A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/192Radicals derived from carboxylic acids from aromatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ602108A 2010-02-18 2011-02-17 Solid forms comprising a cyclopropyl amide derivative NZ602108A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30558110P 2010-02-18 2010-02-18
PCT/SE2011/050170 WO2011102793A1 (en) 2010-02-18 2011-02-17 Solid forms comprising a cyclopropyl amide derivative

Publications (1)

Publication Number Publication Date
NZ602108A true NZ602108A (en) 2014-09-26

Family

ID=44370079

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ602108A NZ602108A (en) 2010-02-18 2011-02-17 Solid forms comprising a cyclopropyl amide derivative

Country Status (17)

Country Link
US (1) US20110201622A1 (enExample)
EP (1) EP2536701A4 (enExample)
JP (1) JP5746718B2 (enExample)
KR (1) KR20130034009A (enExample)
CN (1) CN103140481A (enExample)
AR (1) AR080203A1 (enExample)
AU (1) AU2011218490B9 (enExample)
BR (1) BR112012020780A2 (enExample)
CA (1) CA2789884A1 (enExample)
CL (1) CL2012002285A1 (enExample)
IL (1) IL221430A0 (enExample)
MX (1) MX2012009537A (enExample)
NZ (1) NZ602108A (enExample)
RU (1) RU2012136921A (enExample)
SG (1) SG183231A1 (enExample)
TW (1) TW201136898A (enExample)
WO (1) WO2011102793A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0815591B8 (pt) 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
TW201039825A (en) 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
AU2011218492B2 (en) * 2010-02-18 2014-11-13 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative
CN109438423A (zh) * 2018-09-12 2019-03-08 通化师范学院 一种肺癌靶向化合物azd-3759的合成工艺的新方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (enExample) * 1963-04-04 1900-01-01
US3449427A (en) * 1965-06-03 1969-06-10 Smithkline Corp Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en) * 1970-08-07 1972-10-10 Pfizer Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) * 1970-12-21 1972-08-22 Smith Kline French Lab 5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
EP0435320B1 (en) * 1989-12-29 1994-10-05 Banyu Pharmaceutical Co., Ltd. 2(2-Cyclopropylpyrrolidin-4-ylthio)-carbapenem derivatives
DE4131139A1 (de) * 1991-09-19 1993-03-25 Bayer Ag Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
WO1994020505A1 (en) * 1993-03-12 1994-09-15 The Upjohn Company Crystalline ceftiofur free acid
WO2000000492A1 (en) * 1998-06-26 2000-01-06 Chugai Seiyaku Kabushiki Kaisha FINE POWDER OF L-α-AMINOADIPIC ACID DERIVATIVE, ORAL SOLID PREPARATIONS CONTAINING THE SAME, AND METHOD FOR TREATMENT OF BULK POWDERS
US6284761B1 (en) * 1999-01-08 2001-09-04 Neurogen Corporation 1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
US6521619B2 (en) * 2000-06-29 2003-02-18 Icos Corporation Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
UA75392C2 (en) * 2001-02-23 2006-04-17 Merck & Co Inc N-substituted non-aryl heterocyclic antagonists nmda/nr2b
JP2005508321A (ja) * 2001-09-26 2005-03-31 メルク エンド カムパニー インコーポレーテッド 結晶形態のエルタペネムナトリウム
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN1642947A (zh) * 2002-03-22 2005-07-20 株式会社Lg生命科学 ( 2 S )-N-5-[氨基(亚氨基)甲基]-2-噻吩基甲基-1-( 2 R ) -2-[(羧甲基) 氨基]-3 ,3-二苯基丙酰-2-吡咯烷甲酰胺·nH2O的新晶形
US20040209858A1 (en) * 2002-10-22 2004-10-21 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
US20040077618A1 (en) * 2002-10-22 2004-04-22 Bennani Youssef L. Cycloalkylamides and their therapeutic applications
AU2004238447C1 (en) * 2003-04-23 2009-06-11 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
AR045595A1 (es) * 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
SI1948607T1 (sl) * 2005-09-16 2010-07-30 Janssen Pharmaceutica Nv Ciklopropil amini kot modulatorji histaminskega H3 receptorja
KR20080085031A (ko) * 2006-01-13 2008-09-22 에프. 호프만-라 로슈 아게 사이클로헥실 피페라지닐 메탄온 유도체 및 히스타민 h3수용체 조절제로서의 이의 용도
CN101472887A (zh) * 2006-06-23 2009-07-01 艾博特公司 作为组胺h3受体调节物的环丙胺衍生物
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
TW200828371A (en) * 2006-09-21 2008-07-01 Matsushita Electric Industrial Co Ltd Chip-type filter
BRPI0815591B8 (pt) * 2007-08-22 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, e, uso de um composto.
WO2009043784A1 (en) * 2007-10-04 2009-04-09 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
TW201039825A (en) * 2009-02-20 2010-11-16 Astrazeneca Ab Cyclopropyl amide derivatives 983
AU2011218492B2 (en) * 2010-02-18 2014-11-13 Astrazeneca Ab New crystalline form of a cyclopropyl benzamide derivative

Also Published As

Publication number Publication date
CN103140481A (zh) 2013-06-05
EP2536701A1 (en) 2012-12-26
SG183231A1 (en) 2012-09-27
CA2789884A1 (en) 2011-08-25
BR112012020780A2 (pt) 2016-05-03
KR20130034009A (ko) 2013-04-04
CL2012002285A1 (es) 2013-01-25
WO2011102793A1 (en) 2011-08-25
AU2011218490A1 (en) 2012-10-04
EP2536701A4 (en) 2014-05-07
JP5746718B2 (ja) 2015-07-08
RU2012136921A (ru) 2014-03-27
JP2013520412A (ja) 2013-06-06
AU2011218490B9 (en) 2014-12-18
TW201136898A (en) 2011-11-01
AU2011218490B2 (en) 2014-11-13
US20110201622A1 (en) 2011-08-18
IL221430A0 (en) 2012-10-31
AR080203A1 (es) 2012-03-21
MX2012009537A (es) 2012-08-31

Similar Documents

Publication Publication Date Title
MX2013001614A (es) Compuestos heterociclico.
NZ705135A (en) Heteroaryl compounds and methods of use thereof
NZ601121A (en) 5-alkynyl-pyrimidines
MY176126A (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
PH12015501116A1 (en) New indanyloxydihydrobenzofuranylacetic acids
PH12013500472A1 (en) Piperidinyl-substituted lactams as gpr119 modulators
MX341072B (es) Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol.
MY160785A (en) Manufacturing process for pyrimidine derivatives
EA201171210A1 (ru) Производные оксадиазола
GEP20156319B (en) Asymmetric ureas and medical uses thereof
NZ601920A (en) New crystalline form of a cyclopropyl benzamide derivative
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
NZ701933A (en) Phenoxyethyl piperidine compounds
BR112014014939A2 (pt) composição de tratamento de sementes
BR112014002859A2 (pt) purificação pós-processamento para produção de gama-butiro lactona
NZ602108A (en) Solid forms comprising a cyclopropyl amide derivative
MX2014010910A (es) Sales novedosas de trimebutina basadas en sulfonato.
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
MX2013008699A (es) Compuestos para reducir la produccion de beta-amiloide.
GEP20156395B (en) Synthesis process, and crystalline form of 4-{3-[cis-hexahydrocyclopenta[c]pyrr ol-2(1h)-yl]propoxy}benzamide hydrochloride and pharmaceutical compositions containing thereof
BRPI0909752B8 (pt) processos para a produção de sulfonilpirróis como inibidores de hdac e de uma composição farmacêutica compreendendo os mesmos
TN2013000034A1 (en) Heterocyclic compound and use thereof
GB2527958A (en) Pregnane-oximino-aminoalkylethers and process for preparation thereof, useful as antidiabetic and antidyslipidemic agents
NZ703323A (en) Acrylamide compounds as histamine h3 receptor ligands
RU2009123788A (ru) Способ получения 5-амино-6-метилурацила

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 FEB 2016 BY AJ PARK

Effective date: 20150504

LAPS Patent lapsed